Skip to main content

Table 3 Regression correlation of mRNA expression with clinical traits of aggressive PC in the TCGA cohort: Five candidate genes harbor significant expression associations with aggressive disease traits

From: Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans

Gene Clinical trait OR (CIs) P value FDR
CCDC115 Disease Free Survival 0.67 (0.53–0.85) 0.0007 0.020
Gleason Score 0.73 (0.58–0.91) 0.0063 0.094
DNAJC10 Tumor Stage 0.67 (0.55–0.81) 0.0001 0.007
Gleason Score 0.56 (0.44–0.71) 0.0001 0.007
Disease Free Survival 0.63 (0.46–0.88) 0.0066 0.094
RNF149 Tumor Stage 1.42 (1.12–1.79) 0.0034 0.061
STYXL1 Gleason Score 0.68 (0.55–0.85) 0.0007 0.020
Tumor Stage 0.69 (0.55–0.86) 0.0009 0.021
Nodal Metastasis 0.57 (0.40–0.80) 0.0012 0.025
ZNF502 Gleason Score 1.42 (1.16–1.74 0.0006 0.020